SCHEMBL6640992

SCHEMBL6640992

COc1cc(CC(=O)NCC2CCC(C(N)=O)C2)cc(OC)c1OC

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.47
▸ KMT2A Q03164 3/20 0.47
▸ MEN1 O00255 2/20 0.47
▸ KDM4E B2RXH2 2/20 0.47
▸ HTT P42858 1/20 0.47
▸ MAPK10 P53779 1/20 0.47
▸ MAPK1 P28482 1/20 0.46
▸ SMN1; SMN2 Q16637 3/20 0.46
▸ TDP1 Q9NUW8 1/20 0.46
▸ LMNA P02545 2/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ SIGMAR1 Q99720 1/20 0.43
▸ CCNT1 O60563 1/20 0.43
▸ CCNE1 P24864 1/20 0.43
▸ CDK2 P24941 1/20 0.43
▸ CDK9 P50750 1/20 0.43
▸ CDK5 Q00535 1/20 0.43
▸ CDK5R1 Q15078 1/20 0.43
▸ CTSD P07339 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6640588 0.86 ALDH1A1 (0.49) ALDH1A1KMT2AMEN1KDM4EHTT
SCHEMBL6640586 0.86 ALDH1A1 (0.49) ALDH1A1KMT2AMEN1KDM4EHTT
SCHEMBL6640469 0.84 TDP1 (0.66) KMT2AMEN1MAPK1SMN1; SMN2TDP1
SCHEMBL6640837 0.77 SMN1; SMN2 (0.48) ALDH1A1KDM4EMAPK1SMN1; SMN2TDP1
SCHEMBL6640831 0.77 SMN1; SMN2 (0.48) ALDH1A1KDM4EMAPK1SMN1; SMN2TDP1
SCHEMBL14543978 0.74 SMN1; SMN2 (0.59) ALDH1A1KMT2AMEN1KDM4EHTT
SCHEMBL10744953 0.70 ALDH1A1 (0.56) ALDH1A1KMT2AMEN1KDM4EHTT
SCHEMBL6636713 0.69 POLB (0.50) ALDH1A1KMT2AMEN1KDM4EHTT
SCHEMBL6643674 0.69 TDP1 (0.69) ALDH1A1KMT2AMEN1MAPK1SMN1; SMN2
SCHEMBL6640472 0.69 TDP1 (0.69) ALDH1A1KMT2AMEN1MAPK1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1250340-B1 METHODS AND COMPOUNDS FOR INHIBITING MRP1 LILLY CO ELI (US) 2004-11-17 — — EP disclosed
US-20040176405-A1 Methods and compounds for inhibitting MRP1 KROIN JULIAN (US) 2004-09-09 — — US disclosed
US-6743794-B2 MULTIDRUG RESISTANCE PROTEIN; CANCER; 3-(9-CHLORO-3-METHYL-4-OXO-5H-ISOXAZOLO(4,3-C)QUINOLIN-5-YL)) CYCLOHEXYL)-2-PIPERIDYLACETAMIDE ELI LILLY AND COMPANY 2004-06-01 — — US disclosed
US-20030100576-A1 Methods and compounds for inhibiting mrp1 ELI LILLY AND COMPANY 2003-05-29 — — US disclosed
EP-1250340-A1 METHODS AND COMPOUNDS FOR INHIBITING MRP1 ELI LILLY AND COMPANY (US) 2002-10-23 — — EP disclosed
WO-2001046199-A1 METHODS AND COMPOUNDS FOR INHIBITING MRP1 ELI LILLY AND COMPANY (US) 2001-06-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040176405-A1 Methods and compounds for inhibitting MRP1 ABCC1, ABCB11, ABCB1 ALDH1A1 208/4885KMT2A 4688/4885MEN1 2632/4885
US-20030100576-A1 Methods and compounds for inhibiting mrp1 ABCC1, ABCB11, ABCB1 ALDH1A1 264/4885KMT2A 4622/4885MEN1 3042/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback